Article
Impact of pre-therapy viral load on virological response to modern first-line HAART.
Antiviral therapy - 1 Jan 2013
Santoro Maria Mercedes, Armenia Daniele, Alteri Claudia, Flandre Philippe, Calcagno Andrea, Santoro Mario, Gori Caterina, Fabeni Lavinia, Bellagamba Rita, Borghi Vanni, Forbici Federica, Latini Alessandra, Palamara Guido, Libertone Raffaella, Tozzi Valerio, Boumis Evangelo, Tommasi Chiara, Pinnetti Carmela, Ammassari Adriana, Nicastri Emanuele, Buonomini Annarita, Svicher Valentina, Andreoni Massimo, Narciso Pasquale, Mussini Cristina, Antinori Andrea, Ceccherini-Silberstein Francesca, Di Perri Giovanni, Perno Carlo Federico
Abstract excerpt
BACKGROUND: We tested whether pre-HAART viraemia affects the achievement and maintenance of virological success in HIV-1-infected patients starting modern first-line therapies. METHODS: A total of 1,430 patients starting their first HAART (genotype-tailored) in 2008 (median; IQR: 2006-2009) were grouped according to levels of pre-HAART viraemia (≤ 30,000, 30,001-100,000, 100,001-300,000, 300,001-500,000 and >...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
